Cargando…

Has programmed cell death ligand-1 MET an accomplice in non-small cell lung cancer?—a narrative review

Recently approved and highly specific small-molecule inhibitors of c-MET exon 14 skipping mutations (e.g., capmatinib, tepotinib) are a new and important therapeutic option for the treatment of non-small cell lung cancer (NSCLC) patients harbouring c-MET alterations. Several experimental studies hav...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dempke, Wolfram C. M., Fenchel, Klaus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264346/ https://www.ncbi.nlm.nih.gov/pubmed/34295669 http://dx.doi.org/10.21037/tlcr-21-124

Ejemplares similares

Durvalumab plus novel agents in non-small cell lung cancer—a new COAST on the horizon?
por: Dempke, Wolfram C. M., et al.
Publicado: (2022)

Oncogene alterations in non-small cell lung cancer—have we MET a new target?
por: Dempke, Wolfram C. M., et al.
Publicado: (2022)

Efficacy and Safety of Approved First-Line Tyrosine Kinase Inhibitor Treatments in Metastatic Renal Cell Carcinoma: A Network Meta-Analysis
por: Manz, Kirsi M., et al.
Publicado: (2019)

Tumors' accomplices in invasion
por: Sedwick, Caitlin
Publicado: (2007)

Tumor accomplice: T cell exhaustion induced by chronic inflammation
por: Fang, Liguang, et al.
Publicado: (2022)

Senescent Stromal Cells in the Tumor Microenvironment: Victims or Accomplices?
por: Ye, Minghan, et al.
Publicado: (2023)

Stromal cells in the tumor microenvironment: accomplices of tumor progression?
por: Zhao, Yan, et al.
Publicado: (2023)

A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations
por: Santarpia, Mariacarmela, et al.
Publicado: (2021)

Programmed Death-Ligand-1 Expression in Non-Small Cell Lung Cancer and Prognosis
por: Şahin, Songül, et al.
Publicado: (2019)

Slug and E-Cadherin: Stealth Accomplices?
por: Sterneck, Esta, et al.
Publicado: (2020)

HLA‐C: An Accomplice in Rheumatic Diseases
por: Siegel, Ruby J., et al.
Publicado: (2019)

Excessive intake of sugar: An accomplice of inflammation
por: Ma, Xiao, et al.
Publicado: (2022)

EZH2: An Accomplice of Gastric Cancer
por: Yu, Wuhan, et al.
Publicado: (2023)

Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?
por: Acheampong, Emmanuel, et al.
Publicado: (2019)

Metabolic Remodelling: An Accomplice for New Therapeutic Strategies to Fight Lung Cancer
por: Mendes, Cindy, et al.
Publicado: (2019)

Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
por: Iafolla, Marco A. J., et al.
Publicado: (2017)

Programmed cell death ligand 1 protein levels predicted survival of non-small cell lung cancer
por: Cui, Shaohua, et al.
Publicado: (2017)

Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer
por: D’Arcangelo, Manolo, et al.
Publicado: (2019)

Prevalence of programmed death ligand-1 in patients diagnosed with non-small cell lung cancer in Lebanon
por: Fakhri, Ghina, et al.
Publicado: (2021)

First-line pembrolizumab in programmed death ligand 1 positive non-small cell lung cancer
por: Travert, Camille, et al.
Publicado: (2019)

The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer
por: Bronte, Giuseppe, et al.
Publicado: (2021)

Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancer
por: Nam, Chang Hyun, et al.
Publicado: (2021)

Bending out and breaking away: host-cell accomplices in retroviral escape
por: Yap, Melvyn W, et al.
Publicado: (2004)

Myeloid-Derived Suppressor Cells: A Multifaceted Accomplice in Tumor Progression
por: Cheng, Jia-Nan, et al.
Publicado: (2021)

PA28γ, an Accomplice to Malignant Cancer
por: Lei, Kexin, et al.
Publicado: (2020)

Autophagy, an accomplice or antagonist of drug resistance in HCC?
por: Wu, Yafei, et al.
Publicado: (2021)

Programmed Cell Death Protein 1/Programmed Cell Death Protein Ligand 1 Immunosuppressants in Advanced Non-Small Cell Lung Cancer Research Progress in Treatment
por: Li, Feng, et al.
Publicado: (2022)

Lymphocyte activation gene-3 is associated with programmed death-ligand 1 and programmed cell death protein 1 in small cell lung cancer
por: Sun, Hui, et al.
Publicado: (2021)

BCKDK alters the metabolism of non-small cell lung cancer
por: Wang, Yanhui, et al.
Publicado: (2021)

Landscape of Savolitinib Development for the Treatment of Non-Small Cell Lung Cancer with MET Alteration—A Narrative Review
por: Zhu, Xiaokuan, et al.
Publicado: (2022)

The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer—A Narrative Review
por: Hsu, Robert, et al.
Publicado: (2023)

MET and Small-Cell Lung Cancer
por: Gelsomino, Francesco, et al.
Publicado: (2014)

Programmed death ligand‐1 expression and occult lymph node metastasis in non‐small cell lung cancer
por: Mitsui, Suguru, et al.
Publicado: (2023)

Current and future drug combination strategies based on programmed death-1/programmed death-ligand 1 inhibitors in non-small cell lung cancer
por: Cheng, Ying, et al.
Publicado: (2021)

Intragraft immune cells: accomplices or antagonists of recipient-derived macrophages in allograft fibrosis?
por: Li, Xiaoping, et al.
Publicado: (2023)

Meeting an un-MET need: Targeting MET in non-small cell lung cancer
por: Michaels, Elena, et al.
Publicado: (2022)

Proteasome Inhibitors Diminish c-Met Expression and Induce Cell Death in Non-Small Cell Lung Cancer Cells
por: Li, Yanhui, et al.
Publicado: (2020)

Cancer-Associated Fibroblasts: Accomplices in the Tumor Immune Evasion
por: Hilmi, Marc, et al.
Publicado: (2020)

Unwitting Accomplices: Endocrine Disruptors Confounding Clinical Care
por: Genco, Matthew, et al.
Publicado: (2020)

Tumor-associated macrophages: an accomplice in solid tumor progression
por: Chen, Yibing, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1kbcn9ni097o790scqtd2e09p7